申请人:Sumitomo Dainippon Pharma Co., Ltd.
公开号:US20150238587A1
公开(公告)日:2015-08-27
A compound represented by the formula (1):
wherein X
a
and Y
a
are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R
1
is a hydrogen atom, a group represented by the formula (2):
wherein X
b
and Y
b
are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
由公式(1)表示的化合物:
其中Xa和Ya都是单一键等,癌抗原肽A是一种由7-30个氨基酸残基组成的MHC I类限制性WT1肽,R1是一个氢原子,由公式(2)表示的基团:
其中Xb和Yb都是单一键等,癌抗原肽B具有与癌抗原肽A不同的序列,并且是一种由7-30个氨基酸残基组成的MHC I类限制性WT1肽,或者癌抗原肽C,癌抗原肽C具有与癌抗原肽A不同的序列,是一种由7-30个氨基酸残基组成的MHC I类限制性WT1肽或MHC II类限制性WT1肽,含有一个半胱氨酸残基,或其盐类等。